WO1995017866A1 - Transdermal drug delivery system - Google Patents
Transdermal drug delivery system Download PDFInfo
- Publication number
- WO1995017866A1 WO1995017866A1 PCT/US1994/014222 US9414222W WO9517866A1 WO 1995017866 A1 WO1995017866 A1 WO 1995017866A1 US 9414222 W US9414222 W US 9414222W WO 9517866 A1 WO9517866 A1 WO 9517866A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- drug
- delivery system
- accordance
- indicator
- matrix
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M35/00—Devices for applying media, e.g. remedies, on the human body
- A61M35/003—Portable hand-held applicators having means for dispensing or spreading integral media
- A61M35/006—Portable hand-held applicators having means for dispensing or spreading integral media using sponges, foams, absorbent pads or swabs as spreading means
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- This invention relates to a transdermal drug delivery system, and more particularly, to a drug delivery system in which drug granules are encapsulated within material which controls the release over time of an active ingredient.
- the active ingredient is released into a water retaining matrix.
- Transdermal delivery systems are available, or have been proposed, for many pharmaceutical agents.
- devices used in such techniques are attached to the skin of a patient, usually adhesively.
- the active agent is caused to diffuse from the device through the skin for absorption into the bloodstream.
- the agent is carried throughout the body of the patient.
- Numerous techniques have been proposed to control the rate of release of pharmaceutical agents in transdermal delivery systems. For example, in U.S. Patents Nos.
- U.S. Patent No. 4,409,206 describes a transdermal release system using a skin-compatible polyacrylate, which swells with water and may contain a hydrophilic component to regulate the rate of release.
- U. S. Patent No. 4,624,665 suggests sealing the skin with ah occlusive layer, and transporting a desired dosage of an active agent across the layer from a rate controlling system.
- U.S. Patent No. 4,645,502 discloses an encapsulated permeation enhancer and a dry active agent within an aqueous gelled reservoir.
- U.S. Patent No. 4,690,683 discloses an active pharmaceutical dispersed in a polymeric material to form, by cross-linking, a matrix.
- a solution of the active pharmaceutical may be dispersed in the matrix prior to cross-linking, in which case, the patent says, "micro reservoirs" of the drug are formed in the matrix.
- a suggestion is also made in this patent of the possibility of incorporating a buffering agent into the matrix.
- U.S. Patent 5,149,538, discloses inclusion, in a transdermal delivery system for opioids, of an encapsulated antagonist as a control on the rate of delivery of the opioid.
- the drug delivery system of the present invention takes the form of an occlusive patch, which can be applied to a clean section of skin.
- the occlusion entraps sweat which in turn serves to hydrate the skin
- the entrapped sweat can also saturate a matrix in which a specific drug is dispersed in microencapsulated form.
- the matrix is formulated from gums and gelling agents, so that it absorbs several times its own weight in moisture.
- Drug release from the microcapsules into the matrix depends on the relative ease with which water from the entrapped sweat is able to penetrate the microcapsules' coat to dissolve drug in the inner core.
- the hydrophilic and hydrophobic elements of the coating material can be designed to affect the water permeability of the coating. Dissolved drug then leaches into the matrix and is delivered through the skin to exert the desired effect.
- the present invention also includes a visible indicator, for example, microencapsulated color change indicator, which can be designed, through its formulation, to effect a visible change at significant time points in the lifetime of the patch. Since the mechanism effecting the visible change has a commonality or interrelatedness to that responsible for the release of drug, the manufacture of the indicator can be tailored to represent the status of drug release from the microcapsules. For example, the release of sufficient drug quantity to exert a therapeutic action can be associated with one visible change, and the near exhaustion of drug reserves from the microencapsulated core can be associated with a second visible change. This second feature, in particular, can serve as an indication to the user that a replacement patch should be applied.
- a visible indicator for example, microencapsulated color change indicator
- transdermal route only drugs intended for a prolonged duration of action (i.e., those requiring a sustained release profile) are administered via the transdermal route. This may be due, in part, to the inability to define precisely the quantity and extent of transdermal drug delivery in the short and intermediate terms.
- the use of indicators with transdermal drug delivery systems in accordance with the present invention broadens the utility of drug delivery through the skin by allowing precise accurate indication and evaluation of the process of drug release, and thus the subsequent link to the desired therapeutic activity. This invention, therefore, facilitates exploitation of the transdermal route, where drugs are to be administered through the skin for short or intermediate durations of action, or in controlled release.
- the above-mentioned visible indicator preferably comprises, for example, a layer of microencapsulated colored material visible through the backing of the patch.
- the indicator may advantageously be designed as a system of multiple colored indicators, to represent the significant time points in the process of drug release from the microcapsules.
- one indicator can be engineered to change color when a sufficient quantity of drug, determined to be necessary to initiate therapeutic action, has been released from the microcapsules.
- the indicator can be engineered to change color when the drug reserves in the microcapsules have been depleted, thus providing an easily interpreted visual cue to the useful lifetime of the patch.
- the design of the indicator makes it a particularly suitable model for the process of drug release, since the mechanism responsible for the drug release over time can be engineered to be the same as the release rate responsible for the indicator's visible change.
- the design of the indicator in this invention provides the ability to define and signify the quantity and extent of drug release for short or intermediate durations of action, or in controlled release, therefore broadening the utility of. transdermal therapeutic systems.
- a system in accordance with this invention can be used to deliver drugs such as, for example, quinine derivatives or pyrimethamine, in chemoprophylaxis against malaria.
- drugs such as, for example, quinine derivatives or pyrimethamine
- Children may prefer transdermal medication to the alternative of regular oral medication, and the effectiveness of transdermal medication is not compromised by the presence of concomitant illnesses and symptoms such as vomiting or diarrhea.
- the present system can be engineered to release an antimalarial drug in a "zero order" fashion so that a constant, stable blood concentration can be maintained, thus reducing the likelihood of "breakthrough” infection from fluctuations in blood antimalarial concentration.
- the useful lifetime of the patch can readily be assessed, since the color indicator will change as drug is exhausted.
- the system of this invention can be used to deliver analgesic drugs for example, in peri-operative and post-operative analgesia.
- Analgesics for example, members of the class of non-steroidal anti-inflammatory drugs, such as flurbiprofen
- a transdermal patch for application immediately prior to simple surgical or dental procedures. These patches will be left on the patient for continuing pain relief after the procedure. Such an application reduces the need for parenterally or orally administered pain relief.
- transdermal absorption of the analgesic agent will be unaffected by post operative vomiting, or by the absence of food in the gastrointestinal tract (for example, if the patient should have to undergo a preoperative fast) .
- Further uses could include long-term use for chronic and sub-chronic painful and inflammatory conditions.
- the system of this invention can be used to deliver topical doses of local anesthetic agents prior to minor surgical procedures or before the insertion of intravenous cannulae.
- Local anesthesia in this manner may be of particular advantage where subcutaneous or intradermal injections are a relative contraindication (for example, where such injections will distort the structure of underlying tissue and lead to an increase in scarring) .
- patches can be applied by the patient, a relative or friend, or by a health professional in advance of the procedure.
- Multiple color indicators can then be designed to change with significant time landmarks. For example, one indicator may be used to signify when adequate quantities of local anesthetic should have been released to effect pain relief, and another indicator may signify when most of the dose has been delivered from the patch.
- the system of this invention is useful where constant levels of an antibiotic drug are desirable to prevent or treat recurrent or persistent infections; for example, for the delivery of anti-tuberculous drugs where sustained therapy is indicated.
- a patch containing a drug such as trimethoprim can also be designed to deliver effective levels of the drug to prevent the recurrence of urinary tract infections. This principle is also applicable for protecting susceptible patients (for example, those with a history of rheumatic heart disease) from the risk of heart valve damage from Streptococcus spp. following surgical or dental instrumentation.
- a patch containing a suitable antibiotic drug will be applied immediately before the procedure, and then maintained for an appropriate length of time afterwards, so that a constant level of the drug will be present during the period of risk.
- Specific design of the indicator to change color as the drug reserves are depleted should minimize the likelihood of sub-optimal drug delivery, and result in successful eradication of the pathogenic microbes, or prophylaxis therefrom.
- the system can be designed as a reliable means of delivering drugs to treat patients with central nervous system deficits, for example the anti-psychotic drugs or medications to manage Alzheimer's disease.
- the application of a transdermal therapeutic system is easily supervised by a family member or a care provider who need not have a healthcare background.
- the patch does not require the patient to remember special instructions or to undertake complicated procedures for therapy maintenance, and the color indicators will be useful as a means to assess patient compliance and to assure dose delivery. (For example, if the patch is removed from the skin for any length of time, the indicator's color change would not be observed at the appointed time, and should prompt further investigation.)
- Figure 1 is a schematic side elevation view, in cross-section, showing the structure of a drug delivery system in accordance with the invention.
- Figure 2 is a graph depicting the rate of drug release versus time for a patch designed for slow and sustained release.
- Figure 3 is a graph depicting the rate of drug release versus time for a patch designed for rapid drug release.
- Figure 4 is a graph depicting the rate of drug release versus time for a patch designed for a combination release characteristic (i.e., initially rapid, followed by a sustained release profile) .
- the patch 10 comprises a translucent water-impermeable shell, or backing layer 12.
- the shell 12 provides a reservoir 14 for the other components of the system, described below.
- the shell 12 may be made of a plastic composite, formed by any suitable technique.
- Other suitable materials generally of plastic polymeric composition, may be used for the shell 12, and will occur to those skilled in the art.
- the reservoir 14 may be said to have first and second faces 14a and 14b, the purpose of which is explained below.
- a layer 16 of suitable pressure-sensitive adhesive material is disposed around a flange portion 18 of the shell, and enables the flange portion 18 to be secured to the skin of a user of the patch 10. It will be understood that when the patch 10 is provided to a user, the adhesive layer 16 will ordinarily be covered by a disposable protective layer, not shown.
- the shell 12 When attached to the skin of a user, the shell 12 provides the above-mentioned occlusive covering, which enhances the hydration of the skin area covered by the patch 10. Hydration of the skin area, as will be explained, fosters release and absorption of the drug associated with the patch 10.
- the matrix 20 is formulated to absorb several times its own weight in water, and may comprise, for example, guar, acacia or xanthan gum, or a gelling agent or polymer such as carboxypolymethylene, hydroxyethylcellulose or polyacrylamide. In the case of guar gum, for example, the matrix 20 can be made to absorb between five and ten times its own weight.
- microencapsulated particles of the drug within the matrix 20 in the illustrated form of the invention are microencapsulated particles of the drug.
- the drug microcapsules 22 in the illustrated embodiment include a core or granule 24 of active ingredient or ingredients (drugs) , microencapsulated within a coating material 26.
- the sensitivity of the coating material to the permeation of moisture is controlled by the choice of coating material (for example, acrylate resins, or methylmetacrylic acid co-polymers) , or by its formulation
- Coatings 26 are selected or designed to be more or less susceptible to moisture penetration and subsequent drug core dissolution, according to the desired drug release characteristics. It will be understood that the dissolution of the drug enables it to leach into the matrix 20 for delivery to, and subsequent passage through, the skin of the user.
- microcapsule coating material 26 allows control of the rate of drug release from the core 24.
- a coating 26, that is relatively impervious to moisture, for example, one that is thicker or less permeable because of its physico-chemical properties, or one that contains a higher content of hydrophobic elements in its composition, will result in a more gradual drug release over a sustained period.
- Figure 2 depicts in graphical form a drug release profile for a patch designed for slow and sustained release. This type of release characteristic may be desired for maintaining stable concentrations of drugs for a prolonged duration, for example, in the chemoprophylaxis of malaria.
- a coating 26 that is relatively permeable to water will rapidly release the drug over a short period.
- Figure 3 depicts in graphical form a drug release profile for a patch designed for such rapid release. This may be the goal where the patch is intended to deliver a local anesthetic drug, when a rapid onset, and a subsequent rapid discontinuation of the biological effect is desired. A combination of both release characteristics may be useful in the appropriate setting, for example, in the patch for delivering a drug to effect peri- and post ⁇ operative analgesia, since the goal here is a rapid onset, followed by a sustained maintenance of pain relief.
- Figure 4 depicts in graphical form a drug release profile for a patch of this type. A combination of both the initially rapid release followed by a sustained release profile can be achieved by the incorporation of different "populations" of microcapsules into the patch 10. (For example, microcapsules with coating materials of variable composition and having a variety of water permeability characteristics may be included in the formulation to provide the desired release characteristics) .
- a microencapsulated color indicator designated generally by the reference numeral 28.
- This indicator may be designed to change color in response to the presence of water, electrolyte or other secretion, and may be manufactured from inorganic salts that will change color with hydration (for example, anyhdrous copper sulfate or cobalt chloride) .
- inorganic salts for example, anyhdrous copper sulfate or cobalt chloride
- colorful dyes like amaranth or mercurochrome
- the utility of such an indicator is that it exploits the common mechanism for activating both the indicator's color change and the process for drug release, namely, the ease with which water, electrolyte or other secretion penetrates the coating material of the microcapsules.
- Commonality or interrelatedness of mechanism enables the color indicator to be tailored to accurately reflect the status of drug release from the microcapsules, either by an appropriate choice of coating material or by manipulation of the components in the coating. This feature is advantageous in instances where the timing of the onset, peak, and decline of therapeutic effect is an important consideration in the proper use of the drug.
- a series of different color indicators can be fabricated to change color at time points corresponding to the time of onset of local anesthesia, the time of peak effect, and the time at which the anesthetic effect begins to wear off.
- the color changes that will indicate these important "landmarks" in the lifetime of the patch will very closely reflect the true status (i.e., the quantity and extent) of drug release from the drug microcapsules.
- the commonality of mechanism as between the indicator and the drug release also allows the color change to indicate that successful drug delivery has taken place. This feature will be useful in ensuring compliance to dosing instructions, since the color change will not be achieved without continued contact with the skin. Observation, therefore, that a color change did not occur at the expected time can prompt further investigation.
- Patches in accordance with this invention will have at least one indicator, designed to change color when the drug reserves within the microcapsules are almost exhausted. This feature is intended to prompt the user to discard the old patch and to apply a replacement patch, where required.
- the above-described patches 10 may be used in conjunction with preparatory skin cleanser, containing, for example, alcohol and a weakly buffered acidic or basic solution.
- the solvent would serve to remove surface grease to eliminate a barrier to absorption at the skin, and a buffered acidic or basic solution may be selected according to the physical or chemical properties of the particular drug to be administered and to maximize drug stability and enhance transdermal penetration.
- This invention includes the description of a microencapsulated color change indicator that can be designed, through its formulation, to effect a visible change at significant time points in the lifetime of the patch. Since the dynamics of the mechanism effecting the color change are related to that responsible for the release of drug, the manufacture of the color indicator can be tailored to represent the status of drug release from the microcapsules. For example, the release of sufficient drug quantity to exert a therapeutic action can be associated with one color change indicator, and the near exhaustion of drug reserves from the microencapsulated core can be associated with a second color change. This second feature, in particular, will serve as an indicator to the user that a replacement patch should be applied.
- transdermal route only drugs intended for a prolonged duration of action (i.e., those requiring a sustained release profile) are administered via the transdermal route. This may be due, in part, to the inability to define precisely the quantity and extent of transdermal drug delivery in the short and intermediate terms.
- the use of indicators with transdermal therapeutic systems is a novel concept that should considerably broaden the utility of drug delivery through the skin, by allowing accurate indication of the process of drug release, and thus the subsequent link to the desired therapeutic activity. This invention, therefore, facilitates exploitation of the transdermal route, where there is an intent of administering drugs through the skin for short or intermediate durations of action, or in controlled release.
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP95904868A EP0737052B1 (en) | 1993-12-30 | 1994-12-09 | Transdermal drug delivery system |
NZ277969A NZ277969A (en) | 1993-12-30 | 1994-12-09 | Transdermal drug delivery system containing a drug and a visible indicator |
AT95904868T ATE200210T1 (en) | 1993-12-30 | 1994-12-09 | TRANSDERMAL DRUG DELIVERY SYSTEM |
JP7518054A JPH09507230A (en) | 1993-12-30 | 1994-12-09 | Transdermal drug delivery formulation |
AU13384/95A AU702444B2 (en) | 1993-12-30 | 1994-12-09 | Transdermal drug delivery system |
DK95904868T DK0737052T3 (en) | 1993-12-30 | 1994-12-09 | Transdermal drug delivery system |
DE69427038T DE69427038T2 (en) | 1993-12-30 | 1994-12-09 | TRANSDERMAL MEDICINE ADMINISTRATION SYSTEM |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/176,396 | 1993-12-30 | ||
US08/176,396 US5466465A (en) | 1993-12-30 | 1993-12-30 | Transdermal drug delivery system |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995017866A1 true WO1995017866A1 (en) | 1995-07-06 |
Family
ID=22644188
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1994/014222 WO1995017866A1 (en) | 1993-12-30 | 1994-12-09 | Transdermal drug delivery system |
Country Status (13)
Country | Link |
---|---|
US (2) | US5466465A (en) |
EP (1) | EP0737052B1 (en) |
JP (1) | JPH09507230A (en) |
AT (1) | ATE200210T1 (en) |
AU (1) | AU702444B2 (en) |
CA (1) | CA2179894A1 (en) |
DE (1) | DE69427038T2 (en) |
DK (1) | DK0737052T3 (en) |
ES (1) | ES2160153T3 (en) |
MY (1) | MY114145A (en) |
NZ (1) | NZ277969A (en) |
PT (1) | PT737052E (en) |
WO (1) | WO1995017866A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003024431A1 (en) * | 2001-09-21 | 2003-03-27 | Coloplast A/S | Device for the administration of an active agent to the human skin |
CN109124862A (en) * | 2018-07-12 | 2019-01-04 | 广州馥邦科技应用有限公司 | A kind of control-release long-acting is defervescence plaster used and preparation method thereof |
US11266344B2 (en) * | 2016-09-21 | 2022-03-08 | Samsung Electronics Co., Ltd. | Method for measuring skin condition and electronic device therefor |
Families Citing this family (99)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6861571B1 (en) * | 1994-11-28 | 2005-03-01 | The Procter & Gamble Company | Article having a lotioned topsheet |
GB2307862A (en) * | 1995-12-05 | 1997-06-11 | David Jehan | Patch structures for transdermal therapy |
US5730721A (en) | 1996-01-25 | 1998-03-24 | Vesture Corporation | Medical applicator and method |
US5800832A (en) * | 1996-10-18 | 1998-09-01 | Virotex Corporation | Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces |
US20040047872A1 (en) * | 1996-11-14 | 2004-03-11 | The Government Of The United States, As Represented By The Secretary Of The Army | Indicators for monitoring the technique of transcutaneous immunization |
IT1294748B1 (en) | 1997-09-17 | 1999-04-12 | Permatec Tech Ag | FORMULATION FOR A TRANSDERMAL DEVICE |
US20050048102A1 (en) * | 1997-10-16 | 2005-03-03 | Virotex Corporation | Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces |
US6087341A (en) * | 1998-02-12 | 2000-07-11 | The Board Of Trustees Of The Leland Standford Junior University | Introduction of nucleic acid into skin cells by topical application |
US6475514B1 (en) | 1998-12-03 | 2002-11-05 | Andrew Blitzer | Athletic patch |
EP1148902A1 (en) * | 1999-01-22 | 2001-10-31 | PowderJect Research Limited | Method of enhancing needleless transdermal powdered drug delivery |
US20070196490A1 (en) * | 1999-01-22 | 2007-08-23 | Powderject Research Limited | Method of enhancing needleless transdermal powered drug delivery |
US6337328B1 (en) | 1999-03-01 | 2002-01-08 | Sepracor, Inc. | Bupropion metabolites and methods of use |
EP1168997B1 (en) * | 1999-04-02 | 2013-04-24 | KCI Licensing, Inc. | Vacuum assisted closure system with provision for introduction of agent |
AU5315000A (en) * | 1999-06-03 | 2000-12-28 | Gregory M. Glenn | Indicators for monitoring the technique of transcutaneous immunization |
DE19932603A1 (en) * | 1999-07-13 | 2001-01-25 | Gruenenthal Gmbh | Multi-layer film containing active substance made of in-situ cross-linked hydrophilic polymers |
US6383511B1 (en) | 1999-10-25 | 2002-05-07 | Epicept Corporation | Local prevention or amelioration of pain from surgically closed wounds |
US6926960B1 (en) * | 1999-11-05 | 2005-08-09 | Kao Corporation | Adhesive cleaning sheet |
US6458118B1 (en) * | 2000-02-23 | 2002-10-01 | Medtronic, Inc. | Drug delivery through microencapsulation |
US6455066B1 (en) | 2000-03-10 | 2002-09-24 | Epicept Corporation | Intradermal-penetration agents for topical local anesthetic administration |
US6440096B1 (en) * | 2000-07-14 | 2002-08-27 | Becton, Dickinson And Co. | Microdevice and method of manufacturing a microdevice |
US6682757B1 (en) | 2000-11-16 | 2004-01-27 | Euro-Celtique, S.A. | Titratable dosage transdermal delivery system |
US6576226B1 (en) | 2000-11-17 | 2003-06-10 | Gary R. Jernberg | Local delivery of agents for disruption and inhibition of bacterial biofilm for treatment of periodontal disease |
US6726898B2 (en) | 2000-11-17 | 2004-04-27 | Gary R. Jernberg | Local delivery of agents for disruption and inhibition of bacterial biofilm for treatment of periodontal disease |
US6723077B2 (en) * | 2001-09-28 | 2004-04-20 | Hewlett-Packard Development Company, L.P. | Cutaneous administration system |
US20030175328A1 (en) * | 2002-03-06 | 2003-09-18 | Adi Shefer | Patch for the controlled delivery of cosmetic, dermatological, and pharmaceutical active ingredients into the skin |
US20030175333A1 (en) * | 2002-03-06 | 2003-09-18 | Adi Shefer | Invisible patch for the controlled delivery of cosmetic, dermatological, and pharmaceutical active ingredients onto the skin |
US20040230182A1 (en) * | 2002-12-27 | 2004-11-18 | Medtronic, Inc. | Drug delivery through encapsulation |
AU2003303525A1 (en) * | 2002-12-31 | 2004-07-29 | Ultra-Sonic Technologies, L.L.C. | Transdermal delivery using encapsulated agent activated by ultrasound and/or heat |
US20040191301A1 (en) * | 2003-03-27 | 2004-09-30 | Van Duren Albert Philip | Transdermal device having a phase change material |
EP1620112A4 (en) * | 2003-04-17 | 2007-04-25 | Univ Columbia | Desmoglein 4 is a novel gene involved in hair growth |
US20060200100A1 (en) * | 2003-06-18 | 2006-09-07 | Rosati Coni F | Method and apparatus for supplying gas to an area |
US7651989B2 (en) | 2003-08-29 | 2010-01-26 | Kimberly-Clark Worldwide, Inc. | Single phase color change agents |
US20050074484A1 (en) * | 2003-10-07 | 2005-04-07 | Estanislao Roderico B. | Product for administration of active agents to different areas of the skin |
US7243788B2 (en) * | 2003-10-22 | 2007-07-17 | Kimberly-Clark Worldwide, Inc. | Package for segregating and mixing substances |
IL159273A0 (en) * | 2003-12-09 | 2004-06-01 | Transpharma Medical Ltd | Transdermal delivery system for sustained release of polypeptides |
US20080031898A1 (en) * | 2004-03-26 | 2008-02-07 | David Nathaniel E | Compositions and methods to increase the effect of a neurotoxin treatment |
US7452547B2 (en) * | 2004-03-31 | 2008-11-18 | Johnson&Johnson Consumer Co., Inc. | Product for treating the skin comprising a polyamine microcapsule wall and a skin lightening agent |
DE102004019916A1 (en) * | 2004-04-21 | 2005-11-17 | Grünenthal GmbH | Anti-abuse drug-containing patch |
AU2005238034A1 (en) * | 2004-04-23 | 2005-11-10 | The Trustees Of Columbia University In The City Of New York | Inhibition of hairless protein mRNA |
US7303543B1 (en) | 2004-12-03 | 2007-12-04 | Medtronic Minimed, Inc. | Medication infusion set |
US20060171890A1 (en) * | 2005-01-28 | 2006-08-03 | Yeomans David C | Methods for evaluating the activity of candidate agents |
ES2329930T3 (en) * | 2005-02-11 | 2009-12-02 | Nolabs Ab | DEVICE, METHOD AND USE FOR THE TREATMENT OF NEUROPATHY WITH NITRIC OXIDE. |
US8287923B2 (en) * | 2005-06-10 | 2012-10-16 | Medical College Of Georgia Research Institute, Inc. | Compositions and methods for treating immune disorders |
CA2610757A1 (en) * | 2005-06-10 | 2006-12-14 | Transpharma Medical, Ltd. | Patch for transdermal drug delivery |
US9446017B2 (en) | 2005-08-11 | 2016-09-20 | Augusta University Research Institute, Inc. | Compositions and methods for treating herpes simplex virus |
US8067350B2 (en) | 2005-12-15 | 2011-11-29 | Kimberly-Clark Worldwide, Inc. | Color changing cleansing composition |
US7740879B2 (en) * | 2006-01-17 | 2010-06-22 | Harrogate Holdings | Abuse resistant transdermal drug delivery patch |
US20110150766A1 (en) * | 2006-07-07 | 2011-06-23 | Royds Robert B | Transdermal patch with fatal overdose protection |
US20080008747A1 (en) * | 2006-07-07 | 2008-01-10 | Royds Robert B | Transdermal patch |
PL2054031T3 (en) | 2006-07-21 | 2016-09-30 | Transmucosal delivery devices with enhanced uptake | |
US9114133B2 (en) | 2006-08-25 | 2015-08-25 | U.S. Dept. Of Veterans Affairs | Method of improving diastolic dysfunction |
US20080181932A1 (en) * | 2007-01-30 | 2008-07-31 | Drugtech Corporation | Compositions for oral delivery of pharmaceuticals |
US10154804B2 (en) | 2007-01-31 | 2018-12-18 | Medtronic Minimed, Inc. | Model predictive method and system for controlling and supervising insulin infusion |
US8679541B2 (en) * | 2007-03-14 | 2014-03-25 | Particle Dynamics International, Llc | Spatial arrangement of particles in a drinking device for oral delivery of pharmaceuticals |
US8940326B2 (en) | 2007-03-19 | 2015-01-27 | Vita Sciences Llc | Transdermal patch and method for delivery of vitamin B12 |
US9782090B1 (en) | 2007-03-30 | 2017-10-10 | David G Silverman | Method and system enabling photoplethysmograph measurement of volume status |
US9877681B2 (en) | 2007-03-30 | 2018-01-30 | David G. Silverman | “Micro-patch” for assessment of the local microvasculature and microcirculatory vasoreactivity |
US8961932B2 (en) * | 2007-03-30 | 2015-02-24 | David G. Silverman | “Micro-patch” for assessment of the local microvasculature and microcirculatory vasoreactivity |
US11076772B2 (en) | 2007-03-30 | 2021-08-03 | David G. Silverman | Method and system enabling photoplethysmograph measurement of volume status |
CA2704164A1 (en) * | 2007-10-29 | 2009-05-07 | Transpharma Medical Ltd. | Vertical patch drying |
US20090130017A1 (en) * | 2007-11-19 | 2009-05-21 | Searete Llc | Targeted short-lived drug delivery |
US20090304776A1 (en) * | 2008-06-06 | 2009-12-10 | Totada Shantha | Transmucosal delivery of therapeutic agents and methods of use thereof |
US8690841B2 (en) * | 2009-07-09 | 2014-04-08 | R. Gary Diaz | Wound care system |
EP2459184A1 (en) | 2009-07-31 | 2012-06-06 | The Brigham and Women's Hospital, Inc. | Modulation of sgk1 expression in th17 cells to modulate th17-mediated immune responses |
US20110033515A1 (en) * | 2009-08-04 | 2011-02-10 | Rst Implanted Cell Technology | Tissue contacting material |
US8701671B2 (en) | 2011-02-04 | 2014-04-22 | Joseph E. Kovarik | Non-surgical method and system for reducing snoring |
US9549842B2 (en) | 2011-02-04 | 2017-01-24 | Joseph E. Kovarik | Buccal bioadhesive strip and method of treating snoring and sleep apnea |
CN102884072A (en) | 2010-04-08 | 2013-01-16 | 爱默蕾大学 | Substituted androst-4-ene diones |
US8349358B1 (en) * | 2010-04-15 | 2013-01-08 | Mcbride Emily Vann | Transdermal anesthetic applicator having thermochromic indication |
US20120171277A1 (en) | 2011-01-03 | 2012-07-05 | Royds Robert B | Abuse resistant transdermal drug delivery patch including a release-enhanced antagonist |
US11844720B2 (en) | 2011-02-04 | 2023-12-19 | Seed Health, Inc. | Method and system to reduce the likelihood of dental caries and halitosis |
CA2830069C (en) | 2011-03-20 | 2019-11-12 | The University Of British Columbia | Therapeutic agent for emphysema and copd |
EP2704726B1 (en) | 2011-05-04 | 2018-10-31 | Trustees of Boston University | Proton-motive force stimulation to potentiate aminoglycoside antibiotics against persistent bacteria |
CN103517722B (en) † | 2011-05-26 | 2016-10-19 | 凯希特许有限公司 | The stimulation of fluid used for drip treatment and the system of activation |
US20140227293A1 (en) | 2011-06-30 | 2014-08-14 | Trustees Of Boston University | Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1) |
EP2543370A1 (en) | 2011-07-06 | 2013-01-09 | Georgia Health Sciences University Research Institute, Inc. | Compositions and Methods for Treating Herpes Simplex Virus |
EP2744572B1 (en) | 2011-08-18 | 2017-12-13 | BioDelivery Sciences International, Inc. | Abuse-resistant mucoadhesive devices for delivery of buprenorphine |
US9243037B2 (en) | 2011-11-10 | 2016-01-26 | Trustees Of Boston College | Gramicidin a mutants that function as antibiotics with improved solubility and reduced toxicity |
US9901539B2 (en) | 2011-12-21 | 2018-02-27 | Biodelivery Sciences International, Inc. | Transmucosal drug delivery devices for use in chronic pain relief |
US9192572B2 (en) * | 2012-01-02 | 2015-11-24 | Andrew L. SKIGEN | Oral anesthesia application |
US9687444B2 (en) * | 2012-01-02 | 2017-06-27 | Andrew L. SKIGEN | Veterinary active agent application |
US9693969B2 (en) * | 2012-01-02 | 2017-07-04 | Andrew L. SKIGEN | Mucous membrane active agent application |
KR101335128B1 (en) * | 2012-01-20 | 2013-12-03 | 단국대학교 산학협력단 | A pain relief patch comprising an indicator layer and a preparation method thereof |
JP5908971B2 (en) * | 2012-03-07 | 2016-04-26 | 京セラ株式会社 | PRINTED MATERIAL, ITS MANUFACTURING METHOD, AND PRINTING DEVICE INSPECTION METHOD |
US10583036B2 (en) * | 2013-01-17 | 2020-03-10 | Kanae Technos Co., Ltd. | Topical adhesive skin patch |
US20150366890A1 (en) | 2013-02-25 | 2015-12-24 | Trustees Of Boston University | Compositions and methods for treating fungal infections |
ITMI20130214U1 (en) * | 2013-06-05 | 2014-12-06 | Gianmario Quaglia | DEVICE FOR THE APPLICATION OF LIQUID MEDICAL SUBSTANCES |
GB2521334B (en) * | 2013-08-21 | 2018-06-20 | Univ Swansea | Topical drug patch including microspheres |
CA2924141C (en) | 2013-08-22 | 2022-06-07 | The General Hospital Corporation | 5-amino 4-cyano substituted oxazole and thiazole derivatives as inhibitors of human 12/15-lipoxygenase |
CA2922361C (en) | 2013-08-29 | 2022-07-12 | Trustees Of Boston University | Intermediate metabolism products to potentiate aminoglycoside antibiotics in bacterial infections |
US11839632B2 (en) | 2013-12-20 | 2023-12-12 | Seed Health, Inc. | Topical application of CRISPR-modified bacteria to treat acne vulgaris |
US11826388B2 (en) | 2013-12-20 | 2023-11-28 | Seed Health, Inc. | Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation |
US11833177B2 (en) | 2013-12-20 | 2023-12-05 | Seed Health, Inc. | Probiotic to enhance an individual's skin microbiome |
JP6717829B2 (en) | 2014-12-18 | 2020-07-08 | コーニンクレッカ フィリップス エヌ ヴェKoninklijke Philips N.V. | Hydration status indicator |
EP3303286B1 (en) | 2015-06-01 | 2023-10-04 | Cedars-Sinai Medical Center | Compounds that bind to rela of nf-kb for use in treating cancer |
RU2018107227A (en) | 2015-07-28 | 2019-08-28 | Виоме Терапьютикс Лимитед | THERAPEUTIC AND PREVENTIVE ANTIBACTERIAL MEANS |
JP7035379B2 (en) * | 2017-08-30 | 2022-03-15 | 大日本印刷株式会社 | External patch with time indicator |
GB2582162A (en) * | 2019-03-13 | 2020-09-16 | Singh Arwinder | Transdermal patch |
CN117462836A (en) * | 2023-12-26 | 2024-01-30 | 山东百多安医疗器械股份有限公司 | Functionalized ultrasonic controlled-release puncture dressing patch and preparation method thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4624665A (en) * | 1984-10-01 | 1986-11-25 | Biotek, Inc. | Method of transdermal drug delivery |
US4708716A (en) * | 1983-08-18 | 1987-11-24 | Drug Delivery Systems Inc. | Transdermal drug applicator |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2920500A1 (en) * | 1979-05-21 | 1980-11-27 | Boehringer Sohn Ingelheim | PHARMACEUTICAL PREPARATION IN THE FORM OF A POLYACRYLATE FILM |
US4439199A (en) * | 1980-02-19 | 1984-03-27 | Alza Corporation | Method for administering immunopotentiator |
US4314557A (en) * | 1980-05-19 | 1982-02-09 | Alza Corporation | Dissolution controlled active agent dispenser |
US4379454A (en) * | 1981-02-17 | 1983-04-12 | Alza Corporation | Dosage for coadministering drug and percutaneous absorption enhancer |
US4460372A (en) * | 1981-02-17 | 1984-07-17 | Alza Corporation | Percutaneous absorption enhancer dispenser for use in coadministering drug and percutaneous absorption enhancer |
US4484923A (en) * | 1982-03-25 | 1984-11-27 | Alza Corporation | Method for administering immunopotentiator |
US4963367A (en) * | 1984-04-27 | 1990-10-16 | Medaphore, Inc. | Drug delivery compositions and methods |
US4736866B1 (en) * | 1984-06-22 | 1988-04-12 | Transgenic non-human mammals | |
US4687481A (en) * | 1984-10-01 | 1987-08-18 | Biotek, Inc. | Transdermal drug delivery system |
US4927687A (en) * | 1984-10-01 | 1990-05-22 | Biotek, Inc. | Sustained release transdermal drug delivery composition |
US4824676A (en) * | 1984-10-11 | 1989-04-25 | Schering Corporation | Physiological means of enhancing transdermal delivery of drugs |
US5008111A (en) * | 1984-10-11 | 1991-04-16 | Schering Corporation | Physiological means of enhancing transdermal delivery of drugs |
SE465951B (en) * | 1984-10-23 | 1991-11-25 | Perstorp Ab | ISOMER OF INOSITOL TRIPHOSPHATE PHARMACEUTICAL STATEMENTS FOR SALT FOR USE AS THERAPEUTIC OR PROPHYLACTIC AGENTS AND COMPOSITIONS THEREOF |
US5208036A (en) * | 1985-01-07 | 1993-05-04 | Syntex (U.S.A.) Inc. | N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4946787A (en) * | 1985-01-07 | 1990-08-07 | Syntex (U.S.A.) Inc. | N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4897355A (en) * | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US5049386A (en) * | 1985-01-07 | 1991-09-17 | Syntex (U.S.A.) Inc. | N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4597961A (en) * | 1985-01-23 | 1986-07-01 | Etscorn Frank T | Transcutaneous application of nicotine |
US4645502A (en) * | 1985-05-03 | 1987-02-24 | Alza Corporation | Transdermal delivery of highly ionized fat insoluble drugs |
US4877612A (en) * | 1985-05-20 | 1989-10-31 | Frank M. Berger | Immunological adjuvant and process for preparing the same, pharmaceutical compositions, and process |
US4690683A (en) * | 1985-07-02 | 1987-09-01 | Rutgers, The State University Of New Jersey | Transdermal varapamil delivery device |
WO1987001938A1 (en) * | 1985-09-27 | 1987-04-09 | The Regents Of The University Of California | Liposome transdermal drug delivery system |
US4666441A (en) * | 1985-12-17 | 1987-05-19 | Ciba-Geigy Corporation | Multicompartmentalized transdermal patches |
US4743249A (en) * | 1986-02-14 | 1988-05-10 | Ciba-Geigy Corp. | Dermal and transdermal patches having a discontinuous pattern adhesive layer |
EP0241806A1 (en) * | 1986-04-14 | 1987-10-21 | Fujisawa Pharmaceutical Co., Ltd. | Sustained-release transdermal delivery preparations |
US4725263A (en) * | 1986-07-31 | 1988-02-16 | Medtronic, Inc. | Programmable constant current source transdermal drug delivery system |
US4917688A (en) * | 1987-01-14 | 1990-04-17 | Nelson Research & Development Co. | Bandage for transdermal delivery of systemically-active drug |
US4911707A (en) * | 1987-02-13 | 1990-03-27 | Ciba-Geigy Corporation | Monolithic user-activated transdermal therapeutic system |
NL194728C (en) * | 1987-04-16 | 2003-01-07 | Hollis Eden Pharmaceuticals | Pharmaceutical preparation suitable for the prophylaxis or therapy of a retroviral infection or a complication or consequence thereof. |
US4781924A (en) * | 1987-11-09 | 1988-11-01 | Alza Corporation | Transdermal drug delivery device |
US4837027A (en) * | 1987-11-09 | 1989-06-06 | Alza Corporation | Transdermal drug delivery device |
US5223261A (en) * | 1988-02-26 | 1993-06-29 | Riker Laboratories, Inc. | Transdermal estradiol delivery system |
US4994278A (en) * | 1988-03-04 | 1991-02-19 | Noven Pharmaceuticals, Inc. | Breathable backing |
US5032402A (en) * | 1988-10-27 | 1991-07-16 | The University Of Kentucky Research Foundation | 3-hydroxy-N-methylpyrrolidone and use as transdermal enhancer |
US4973708A (en) * | 1988-10-27 | 1990-11-27 | University Of Kentucky Research Foundation | 3-hydroxy-N-methylpyrrolidone and preparation thereof |
DE3910543A1 (en) * | 1989-04-01 | 1990-10-11 | Lohmann Therapie Syst Lts | TRANSDERMAL THERAPEUTIC SYSTEM WITH INCREASED ACTIVE FLUID AND METHOD FOR THE PRODUCTION THEREOF |
US5050612A (en) * | 1989-09-12 | 1991-09-24 | Matsumura Kenneth N | Device for computer-assisted monitoring of the body |
US5194451A (en) * | 1989-11-02 | 1993-03-16 | Katz David H | Systemic anti-inflammatory treatment |
US5166219A (en) * | 1989-11-02 | 1992-11-24 | Lidak Pharmaceuticals | Systemic anti-inflammatory treatment |
US5149538A (en) * | 1991-06-14 | 1992-09-22 | Warner-Lambert Company | Misuse-resistive transdermal opioid dosage form |
US5234690A (en) * | 1991-08-23 | 1993-08-10 | Cygnus Therapeutic Systems | Transdermal drug delivery device using an unfilled microporous membrane to achieve delayed onset |
US5230897A (en) * | 1991-10-31 | 1993-07-27 | G. D. Searle & Co. | Transdermal pentamidine |
US5756117A (en) * | 1992-04-08 | 1998-05-26 | International Medical Asscociates, Inc. | Multidose transdermal drug delivery system |
-
1993
- 1993-12-30 US US08/176,396 patent/US5466465A/en not_active Expired - Fee Related
-
1994
- 1994-12-09 CA CA002179894A patent/CA2179894A1/en not_active Abandoned
- 1994-12-09 PT PT95904868T patent/PT737052E/en unknown
- 1994-12-09 AT AT95904868T patent/ATE200210T1/en not_active IP Right Cessation
- 1994-12-09 JP JP7518054A patent/JPH09507230A/en not_active Ceased
- 1994-12-09 DK DK95904868T patent/DK0737052T3/en active
- 1994-12-09 WO PCT/US1994/014222 patent/WO1995017866A1/en active IP Right Grant
- 1994-12-09 NZ NZ277969A patent/NZ277969A/en unknown
- 1994-12-09 ES ES95904868T patent/ES2160153T3/en not_active Expired - Lifetime
- 1994-12-09 DE DE69427038T patent/DE69427038T2/en not_active Expired - Fee Related
- 1994-12-09 EP EP95904868A patent/EP0737052B1/en not_active Expired - Lifetime
- 1994-12-09 AU AU13384/95A patent/AU702444B2/en not_active Ceased
- 1994-12-29 MY MYPI94003554A patent/MY114145A/en unknown
-
1995
- 1995-06-07 US US08/477,914 patent/US5667798A/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4708716A (en) * | 1983-08-18 | 1987-11-24 | Drug Delivery Systems Inc. | Transdermal drug applicator |
US4624665A (en) * | 1984-10-01 | 1986-11-25 | Biotek, Inc. | Method of transdermal drug delivery |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003024431A1 (en) * | 2001-09-21 | 2003-03-27 | Coloplast A/S | Device for the administration of an active agent to the human skin |
US8197843B2 (en) | 2001-09-21 | 2012-06-12 | Coloplast A/S | Device for the administration of an active agent to the human skin |
US11266344B2 (en) * | 2016-09-21 | 2022-03-08 | Samsung Electronics Co., Ltd. | Method for measuring skin condition and electronic device therefor |
CN109124862A (en) * | 2018-07-12 | 2019-01-04 | 广州馥邦科技应用有限公司 | A kind of control-release long-acting is defervescence plaster used and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
MY114145A (en) | 2002-08-30 |
DK0737052T3 (en) | 2001-05-07 |
US5466465A (en) | 1995-11-14 |
CA2179894A1 (en) | 1995-07-06 |
EP0737052A1 (en) | 1996-10-16 |
ATE200210T1 (en) | 2001-04-15 |
AU702444B2 (en) | 1999-02-18 |
EP0737052A4 (en) | 1997-10-15 |
NZ277969A (en) | 1998-01-26 |
EP0737052B1 (en) | 2001-04-04 |
PT737052E (en) | 2001-07-31 |
DE69427038T2 (en) | 2001-07-19 |
ES2160153T3 (en) | 2001-11-01 |
US5667798A (en) | 1997-09-16 |
JPH09507230A (en) | 1997-07-22 |
DE69427038D1 (en) | 2001-05-10 |
AU1338495A (en) | 1995-07-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5466465A (en) | Transdermal drug delivery system | |
CN105431175B (en) | transdermal delivery system | |
ES2285704T3 (en) | NEW FORMULATIONS FOR THE TRANSDERMIC ADMINISTRATION OF PERGOLIDA. | |
JP2552190B2 (en) | Therapeutic agents for delayed and controlled transdermal or mucus administration of active substances | |
EP1814531B1 (en) | Transdermal delivery systems | |
CA2654700C (en) | Transdermal patch | |
JPS59186564A (en) | Medicine admistering apparatus | |
JPH01135717A (en) | Improved drug percataneous supply apparatus | |
CN105579074A (en) | Dressing system | |
US20040191301A1 (en) | Transdermal device having a phase change material | |
EP1905433A1 (en) | Percutaneous absorption patch with application position indicating function, and iontophoresis device | |
AU2006215805B2 (en) | Method for a treatment with a medicament combination and medicament combinations suitable for the same | |
EP1589955B1 (en) | Transdermal therapeutic system suitable for heat application for promoting the permeation of active substances, and the use thereof | |
JP2007044258A (en) | Percutaneous absorption patch with a syringe needle insertion hole | |
AU1006899A (en) | Transdermal drug delivery system | |
Panerai et al. | Baclofen prolongs the analgesic effect of fentanyl in man | |
EP2408440B1 (en) | Transdermal pharmaceutical preparation and administration of tirofiban | |
Streisand et al. | Newer drug delivery systems | |
RIPAMONTI et al. | Alternative routes for systemic opioid delivery | |
US20240050361A1 (en) | Topical product hands-free applicator drug delivery system and methods of making and using the same | |
Gilberto et al. | Use of three infusion pumps for postoperative administration of buprenorphine or morphine in dogs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU JP KE KG KP KR KZ LK LT LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE MW SD SZ AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2179894 Country of ref document: CA Ref document number: 277969 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1995904868 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1995904868 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 1995904868 Country of ref document: EP |